TY - JOUR
T1 - A global collaboration for systematic analysis of broad-ranging antibodies against the SARS-CoV-2 spike protein
AU - The CoVIC-DB Team
AU - Coronavirus Immunotherapeutic Consortium
AU - Schendel, Sharon L.
AU - Yu, Xiaoying
AU - Halfmann, Peter J.
AU - Mahita, Jarjapu
AU - Ha, Brendan
AU - Hastie, Kathryn M.
AU - Li, Haoyang
AU - Bedinger, Daniel
AU - Troup, Camille
AU - Li, Kan
AU - Kuzmina, Natalia
AU - Torrelles, Jordi B.
AU - Munt, Jennifer E.
AU - Maddocks, Melissa
AU - Osei-Twum, Mary
AU - Callaway, Heather M.
AU - Reece, Stephen
AU - Palser, Anne
AU - Kellam, Paul
AU - Dennison, S. Moses
AU - Huntwork, Richard H.C.
AU - Horn, Gillian Q.
AU - Abraha, Milite
AU - Feeney, Elizabeth
AU - Martinez-Sobrido, Luis
AU - Pino, Paula A.
AU - Hicks, Amberlee
AU - Ye, Chengjin
AU - Park, Jun Gyu
AU - Maingot, Billie
AU - Periasamy, Sivakumar
AU - Mallory, Michael
AU - Scobey, Trevor
AU - Lepage, Marie Noelle
AU - St-Amant, Natalie
AU - Khan, Sarwat
AU - Gambiez, Anaïs
AU - Baric, Ralph S.
AU - Bukreyev, Alexander
AU - Gagnon, Luc
AU - Germann, Timothy
AU - Kawaoka, Yoshihiro
AU - Tomaras, Georgia D.
AU - Peters, Bjoern
AU - Saphire, Erica Ollmann
N1 - Publisher Copyright:
© 2025 The Authors
PY - 2025/4/22
Y1 - 2025/4/22
N2 - The Coronavirus Immunotherapeutic Consortium (CoVIC) conducted side-by-side comparisons of over 400 anti-SARS-CoV-2 spike therapeutic antibody candidates contributed by large and small companies as well as academic groups on multiple continents. Nine reference labs analyzed antibody features, including in vivo protection in a mouse model of infection, spike protein affinity, high-resolution epitope binning, ACE-2 binding blockage, structures, and neutralization of pseudovirus and authentic virus infection, to build a publicly accessible dataset in the database CoVIC-DB. High-throughput, high-resolution binning of CoVIC antibodies defines a broad and predictive landscape of antibody epitopes on the SARS-CoV-2 spike protein and identifies features associated with durable potency against multiple SARS-CoV-2 variants of concern and high in vivo efficacy. Results of the CoVIC studies provide a guide for selecting effective and durable antibody therapeutics and for immunogen design as well as providing a framework for rapid response to future viral disease outbreaks.
AB - The Coronavirus Immunotherapeutic Consortium (CoVIC) conducted side-by-side comparisons of over 400 anti-SARS-CoV-2 spike therapeutic antibody candidates contributed by large and small companies as well as academic groups on multiple continents. Nine reference labs analyzed antibody features, including in vivo protection in a mouse model of infection, spike protein affinity, high-resolution epitope binning, ACE-2 binding blockage, structures, and neutralization of pseudovirus and authentic virus infection, to build a publicly accessible dataset in the database CoVIC-DB. High-throughput, high-resolution binning of CoVIC antibodies defines a broad and predictive landscape of antibody epitopes on the SARS-CoV-2 spike protein and identifies features associated with durable potency against multiple SARS-CoV-2 variants of concern and high in vivo efficacy. Results of the CoVIC studies provide a guide for selecting effective and durable antibody therapeutics and for immunogen design as well as providing a framework for rapid response to future viral disease outbreaks.
KW - coronavirus
KW - COVID-19
KW - CP: Immunology
KW - high-resolution epitope binning
KW - neutralization
KW - SARS-CoV-2 spike protein
KW - therapeutic antibodies
UR - http://www.scopus.com/inward/record.url?scp=105001592906&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=105001592906&partnerID=8YFLogxK
U2 - 10.1016/j.celrep.2025.115499
DO - 10.1016/j.celrep.2025.115499
M3 - Article
C2 - 40184253
AN - SCOPUS:105001592906
SN - 2211-1247
VL - 44
JO - Cell Reports
JF - Cell Reports
IS - 4
M1 - 115499
ER -